UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934
| |
Date of Report (Date of earliest event reported):
May 2, 2006 (May 1, 2006) |
REGENERON PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
| |
|
|
|
|
| New York |
|
000-19034 |
|
133444607 |
| (State or other jurisdiction of
|
|
(Commission File Number)
|
|
(I.R.S. Employer |
| incorporation)
|
|
|
|
Identification Number) |
| |
|
|
777 Old Saw Mill River Road, Tarrytown, New York
|
|
10591-6707 |
| |
(Address of principal executive offices)
|
|
(Zip Code) |
(914) 347-7000
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
TABLE OF CONTENTS
|
|
|
| Item 7.01 |
|
Regulation FD Disclosure |
On May 1, 2006, the Company issued a press release announcing positive
preliminary results from its phase 1 trial of the Vascular Endothelial Growth
Factor (VEGF) Trap in patients with the neovascular form of age-related macular
degeneration. A copy of the press release is included as Exhibit 99(a) to this
Current Report on Form 8-K.
|
|
|
| Item 9.01 |
|
Financial Statements and Exhibits |
| |
|
|
|
|
(c) Exhibits |
|
|
|
|
|
99(a) Press Release of Regeneron Pharmaceuticals, Inc. dated May 1, 2006. |
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
|
|
|
|
|
|
| |
|
REGENERON PHARMACEUTICALS, INC. |
|
|
|
|
|
|
|
|
|
Dated: May 2, 2006
|
|
By:
|
|
/s/ Stuart Kolinski
Stuart Kolinski
|
|
|
|
|
|
|
Vice President and General Counsel |
|
|
2